Avanos Medical (AVNS) EPS (Weighted Average and Diluted) (2014 - 2026)

Avanos Medical has disclosed EPS (Weighted Average and Diluted) across 13 years of filings, most recently posting $0.11 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.11, down 21.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.6 (up 80.51% YoY), and the FY2025 annual result was -$1.57, up 81.31% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.11 for Q1 2026 at Avanos Medical, up from -$0.02 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.24 in Q4 2023 to a low of -$8.51 in Q4 2024.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.04 (2024), against an average of -$0.62.
• Peak annual rise in EPS (Weighted Average and Diluted) reached 1300.0% in 2025, while the deepest fall reached 4250.0% in 2025.
• Avanos Medical's EPS (Weighted Average and Diluted) stood at $0.21 in 2022, then climbed by 14.29% to $0.24 in 2023, then sank by 3645.83% to -$8.51 in 2024, then surged by 99.76% to -$0.02 in 2025, then soared by 650.0% to $0.11 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.11 (Q1 2026), -$0.02 (Q4 2025), and -$0.03 (Q3 2025), per Business Quant data.